20 articles
Real-world study of 664 patients reveals effective treatment options after T-DXd discontinuation, with low lung disease recurrence rates.
A randomized trial shows hormone receptor-positive/HER2+ early breast cancer patients had 100% 5-year overall survival with endocrine therapy plus dual HER2 blockade.
ASTER 70s trial compares treatment intensities for women 70+ with genomically high-risk breast cancer to optimize outcomes while minimizing toxicity.
Japanese trial shows dual HER2 blockade with pertuzumab plus trastuzumab improves overall survival even after prior pertuzumab treatment.
The BEGONIA trial finds durvalumab combined with trastuzumab deruxtecan achieves 62% response rate in hard-to-treat metastatic breast cancer.
Innovative treatment combining three powerful drugs achieved 85% progression-free survival at one year in high-risk patients.
Phase 1 data from 15 heavily pretreated Japanese myeloma patients confirms talquetamab's safety and efficacy, matching global trial results.
A phase 1 trial shows Temferon โ a gene-engineered stem cell therapy โ safely delivers interferon-ฮฑ into glioblastoma tumors with no dose-limiting toxicities.
New study shows circulating tumor cells can predict treatment response and reveal drug resistance patterns.
Tucatinib-based treatment extends survival from 4.4 to 10 months for women with breast cancer that spread to brain lining.
Early PSMA upregulation after enzalutamide predicts shorter survival, but adding Lu-177-PSMA-617 improves outcomes in resistant prostate cancer.
A multinational study of 4,913 patients finds EBRT delivers survival outcomes comparable to surgery and ablation for early hepatocellular carcinoma.
Trastuzumab deruxtecan demonstrates potential benefits in treating residual HER2-positive early breast cancer patients.
Researchers found that stopping HER2 protein degradation significantly improves trastuzumab deruxtecan cancer treatment outcomes.
High-level randomized evidence quantifies genitourinary toxicity burden over time following prostate radiotherapy, with direct implications for treatment decisions.
A comprehensive review reveals how iron-driven cell death can be exploited to treat ATC, one of the most lethal human cancers.
A 73-patient study finds PD-L1 expression and TERT mutations identify high-grade thyroid cancers most likely to benefit from checkpoint inhibitor therapy.
A new 'induce-target-kill' strategy uses TROP2-directed ADCs to eliminate drug-tolerant persister cells in EGFR-mutant lung cancer.
Researchers use advanced cell profiling to develop personalized immune treatments for thyroid cancer patients.
A first-in-human trial shows CAR-modified stem cell memory T cells outperform standard CAR T cells in expansion, persistence, and complete responses.
